Tammo Ostendorf

List of Publications by Year
in descending order

54 papers	3,245 citations	159525 30 h-index	175177 52 g-index
54 all docs	54 docs citations	54 times ranked	3715 citing authors

#	Article	IF	Citations
1	Renal fibrosis: novel insights into mechanisms and therapeutic targets. Nature Reviews Nephrology, 2010, 6, 643-656.	4.1	517
2	Mesenchymal Stem Cells Prevent Progressive Experimental Renal Failure but Maldifferentiate into Glomerular Adipocytes. Journal of the American Society of Nephrology: JASN, 2007, 18, 1754-1764.	3.0	265
3	Novel Approach to Specific Growth Factor Inhibition in Vivo. American Journal of Pathology, 1999, 154, 169-179.	1.9	239
4	Pro-fibrogenic potential of PDGF-D in liver fibrosis. Journal of Hepatology, 2007, 46, 1064-1074.	1.8	164
5	Treatment targets in renal fibrosis. Nephrology Dialysis Transplantation, 2007, 22, 3391-3407.	0.4	132
6	Specific Antagonism of PDGF Prevents Renal Scarring in Experimental Glomerulonephritis. Journal of the American Society of Nephrology: JASN, 2001, 12, 909-918.	3.0	112
7	PDGF-C Is a Proinflammatory Cytokine that Mediates Renal Interstitial Fibrosis. Journal of the American Society of Nephrology: JASN, 2008, 19, 281-289.	3.0	103
8	Complement C5 Mediates Experimental Tubulointerstitial Fibrosis. Journal of the American Society of Nephrology: JASN, 2007, 18, 1508-1515.	3.0	100
9	A Fully Human Monoclonal Antibody (CR002) Identifies PDGF-D as a Novel Mediator of Mesangioproliferative Glomerulonephritis. Journal of the American Society of Nephrology: JASN, 2003, 14, 2237-2247.	3.0	87
10	PDGF and the progression of renal disease. Nephrology Dialysis Transplantation, 2014, 29, i45-i54.	0.4	82
11	Detection of Activated Parietal Epithelial Cells on the Glomerular Tuft Distinguishes Early Focal Segmental Glomerulosclerosis from Minimal Change Disease. American Journal of Pathology, 2014, 184, 3239-3248.	1.9	81
12	PDGF-C Expression in the Developing and Normal Adult Human Kidney and in Glomerular Diseases. Journal of the American Society of Nephrology: JASN, 2003, 14, 1145-1153.	3.0	69
13	The PDGF family in renal fibrosis. Pediatric Nephrology, 2012, 27, 1041-1050.	0.9	67
14	Antagonism of PDGF-D by Human Antibody CR002 Prevents Renal Scarring in Experimental Glomerulonephritis. Journal of the American Society of Nephrology: JASN, 2006, 17, 1054-1062.	3.0	64
15	Expression of a Novel PDGF Isoform, PDGF-C, in Normal and Diseased Rat Kidney. Journal of the American Society of Nephrology: JASN, 2002, 13, 910-917.	3.0	62
16	Macrophage Migration Inhibitory Factor Mediates Proliferative GN via CD74. Journal of the American Society of Nephrology: JASN, 2016, 27, 1650-1664.	3.0	59
17	Common histological patterns in glomerular epithelial cells in secondary focal segmental glomerulosclerosis. Kidney International, 2015, 88, 990-998.	2.6	57
18	PDGF-D inhibition by CR002 ameliorates tubulointerstitial fibrosis following experimental glomerulonephritis. Nephrology Dialysis Transplantation, 2007, 22, 1323-1331.	0.4	55

#	Article	IF	Citations
19	CD44 is required for the pathogenesis of experimental crescentic glomerulonephritis and collapsing focal segmental glomerulosclerosis. Kidney International, 2018, 93, 626-642.	2.6	52
20	Key metalloproteinase-mediated pathways in the kidney. Nature Reviews Nephrology, 2021, 17, 513-527.	4.1	46
21	The Effects of Platelet-Derived Growth Factor Antagonism in Experimental Glomerulonephritis Are Independent of the Transforming Growth Factorâ€"Î² System. Journal of the American Society of Nephrology: JASN, 2002, 13, 658-667.	3.0	46
22	IL-6 Trans-Signaling Drives Murine Crescentic GN. Journal of the American Society of Nephrology: JASN, 2016, 27, 132-142.	3.0	45
23	Platelet-derived growth factors (PDGFs) in glomerular and tubulointerstitial fibrosis. Kidney International Supplements, 2014, 4, 65-69.	4.6	44
24	Diffusionâ€weighted MRI does not reflect kidney fibrosis in a rat model of fibrosis. Journal of Magnetic Resonance Imaging, 2015, 42, 990-998.	1.9	44
25	Y-Box Protein 1 Mediates PDGF-B Effects in Mesangioproliferative Glomerular Disease. Journal of the American Society of Nephrology: JASN, 2005, 16, 2985-2996.	3.0	42
26	Extracellular YB-1 Blockade in Experimental Nephritis Upregulates Notch-3 Receptor Expression and Signaling. Nephron Experimental Nephrology, 2011, 118, e100-e108.	2.4	41
27	Selective Cyclooxygenase-2 Inhibition Impairs Glomerular Capillary Healing in Experimental Glomerulonephritis. Journal of the American Society of Nephrology: JASN, 2002, 13, 1261-1270.	3.0	40
28	PDGF-C Mediates Glomerular Capillary Repair. American Journal of Pathology, 2010, 177, 58-69.	1.9	38
29	Calcineurin-mediated YB-1 Dephosphorylation Regulates CCL5 Expression during Monocyte Differentiation. Journal of Biological Chemistry, 2014, 289, 21401-21412.	1.6	33
30	Therapeutic nuclear shuttling of YB-1 reduces renal damage and fibrosis. Kidney International, 2016, 90, 1226-1237.	2.6	32
31	A Novel Role for GATA3 in Mesangial Cells in Glomerular Development and Injury. Journal of the American Society of Nephrology: JASN, 2019, 30, 1641-1658.	3.0	31
32	Patients with IgA nephropathy exhibit high systemic PDGF-DD levels. Nephrology Dialysis Transplantation, 2009, 24, 2755-2762.	0.4	26
33	Inducible Nitric Oxide Synthase-Derived Nitric Oxide Promotes Glomerular Angiogenesis via Upregulation of Vascular Endothelial Growth Factor Receptors. Journal of the American Society of Nephrology: JASN, 2004, 15, 2307-2319.	3.0	25
34	A Novel, Dual Role of CCN3 in Experimental Glomerulonephritis. American Journal of Pathology, 2012, 180, 1979-1990.	1.9	25
35	Effects and mechanisms of angiotensin II receptor blockade with telmisartan in a normotensive model of mesangioproliferative nephritis. Nephrology Dialysis Transplantation, 2011, 26, 3131-3143.	0.4	24
36	Growth arrestâ€"specific protein 1 is a novel endogenous inhibitor of glomerular cell activation and proliferation. Kidney International, 2013, 83, 251-263.	2.6	24

#	Article	IF	Citations
37	Complement C5a receptors C5L2 and C5aR in renal fibrosis. American Journal of Physiology - Renal Physiology, 2018, 314, F35-F46.	1.3	24
38	<scp>YB</scp>â€1 orchestrates onset and resolution of renal inflammation via <scp>IL</scp>10 gene regulation. Journal of Cellular and Molecular Medicine, 2017, 21, 3494-3505.	1.6	23
39	High-fat diet-induced obesity causes an inflammatory microenvironment in the kidneys of aging Long-Evans rats. Journal of Inflammation, 2019, 16, 14.	1.5	21
40	New Aspects of Kidney Fibrosisâ€"From Mechanisms of Injury to Modulation of Disease. Frontiers in Medicine, 2021, 8, 814497.	1.2	21
41	Gp130-dependent signaling in the podocyte. American Journal of Physiology - Renal Physiology, 2014, 307, F346-F355.	1.3	20
42	Renal side effects of anti-VEGF therapy in man: a new test system. Nephrology Dialysis Transplantation, 2007, 22, 2778-2780.	0.4	19
43	Role of Platelet-Derived Growth Factor-CC in Capillary Rarefaction in Renal Fibrosis. American Journal of Pathology, 2015, 185, 2132-2142.	1.9	19
44	The YB-1:Notch-3 axis modulates immune cell responses and organ damage in systemic lupus erythematosus. Kidney International, 2020, 97, 289-303.	2.6	18
45	Biological responses to PDGF-AA versus PDGF-CC in renal fibroblasts. Nephrology Dialysis Transplantation, 2013, 28, 889-900.	0.4	16
46	Identification of platelet-derived growth factor C as a mediator of both renal fibrosis and hypertension. Kidney International, 2019, 95, 1103-1119.	2.6	14
47	The nucleic acid binding protein YB-1â€"controlled expression of CXCL-1 modulates kidney damage inÂliver fibrosis. Kidney International, 2020, 97, 741-752.	2.6	13
48	PDGF-D and Renal Disease: Yet Another One of Those Growth Factors?. Journal of the American Society of Nephrology: JASN, 2003, 14, 2690-2691.	3.0	12
49	The Role of PDGF-D in Mesangioproliferative Glomerulonephritis. , 2007, 157, 153-158.		12
50	Late angiotensin <scp>II</scp> receptor blockade in progressive rat mesangioproliferative glomerulonephritis: new insights into mechanisms. Journal of Pathology, 2013, 229, 672-684.	2.1	12
51	Cold Shock Proteins Mediate GN with Mesangioproliferation. Journal of the American Society of Nephrology: JASN, 2016, 27, 3678-3689.	3.0	10
52	YB-1 increases glomerular, but decreases interstitial fibrosis in CNI-induced nephropathy. Clinical Immunology, 2018, 194, 67-74.	1.4	10
53	Anti-interleukin-6 therapy through application of a monogenic protein inhibitor via gene delivery. Scientific Reports, 2015, 5, 14685.	1.6	8
54	Cytokines and Growth Factors. , 2009, , 243-265.		0